Tech
DeepMind's AlphaGenome 2 adds DNA methylation to predicted readouts and adapts to new single-cell data without retraining.
Google DeepMind · SiliconANGLE · University of Cambridge · 2026-11-11 · Source ↗
DeepMind's AlphaGenome 2 adds DNA methylation to predicted readouts and adapts to new single-cell data without retraining.
Google DeepMind · SiliconANGLE · University of Cambridge · 2026-11-11 · Source ↗
DeepMind dropped AlphaGenome 2 the same day as Gemini Robotics 2.5 and framed it as the next step in its biological-sequence modeling arc from AlphaFold forward. The new model keeps the three readouts the first generation predicted: gene expression (which genes are on, and how strongly), histone modification (the epigenetic marks that regulate access to DNA), and chromatin accessibility (which DNA regions are open to transcription machinery). It adds DNA methylation, a key regulator of gene silencing that previous DeepMind genomic models did not predict end-to-end.
Cell types and conditioning
Crucially, AlphaGenome 2 is conditioned on single-cell data from the Human Cell Atlas initiative, which has mapped gene-expression patterns across millions of individual cells in hundreds of tissue types. DeepMind's framing: the same DNA sequence produces very different behavior in a heart muscle cell than in an immune cell, and the model has to know which cell state it is predicting. Professor Sarah Teichmann, co-founder of the Human Cell Atlas and Cambridge professor of Stem Cell Medicine, said the model can adapt even from "very small samples," which matters for rare-disease and under-sampled-tissue contexts where there is no practical path to retraining a frontier model.
"Adapts directly to new single-cell data without retraining." — Prof. Sarah Teichmann, Human Cell Atlas / University of Cambridge, 2026-11-11
Scope and limits
The model is meant for research use, not clinical diagnostics. DeepMind said predictions are intended to guide experimental design rather than replace wet-lab validation, and the model is explicitly not approved for clinical or diagnostic use. No quantitative benchmark table accompanied the launch coverage; DeepMind's own paper, benchmark splits, and availability terms were not reported in the SiliconANGLE write-up. The release fits a cadence: AlphaGenome v1 landed in June 2025, and DeepMind has since expanded along the "digital biology" axis with AlphaProof Code for Lean verification of Signal (announced November 10) and now AlphaGenome 2 for epigenetic prediction.